GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Absci Corp (NAS:ABSI) » Definitions » Change In Receivables

Absci (ABSI) Change In Receivables : $1.23 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Absci Change In Receivables?

Absci's change in receivables for the quarter that ended in Mar. 2024 was $2.15 Mil. It means Absci's Accounts Receivable declined by $2.15 Mil from Dec. 2023 to Mar. 2024 .

Absci's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.67 Mil. It means Absci's Accounts Receivable increased by $0.67 Mil from Dec. 2022 to Dec. 2023 .

Absci's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Absci's Days Sales Outstanding for the three months ended in Mar. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Absci's liquidation value for the three months ended in Mar. 2024 was $126.75 Mil.


Absci Change In Receivables Historical Data

The historical data trend for Absci's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Absci Change In Receivables Chart

Absci Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
-0.10 -1.37 0.23 -0.15 -0.67

Absci Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 -1.83 2.31 -1.39 2.15

Absci Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Absci  (NAS:ABSI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Absci's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0.898*91
=0.00

2. In Ben Graham's calculation of liquidation value, Absci's accounts receivable are only considered to be worth 75% of book value:

Absci's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=161.543-34.791+0.75 * 0+0.5 * 0
=126.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Absci Change In Receivables Related Terms

Thank you for viewing the detailed overview of Absci's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Absci (ABSI) Business Description

Traded in Other Exchanges
N/A
Address
18105 SE Mill Plain Boulevard, Vancouver, WA, USA, 98683
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Executives
Frans Van Houten director 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Daniel A Rabinovitsj director 400 W CESAR CHAVEZ, AUSTIN TX 78701
Andreas Busch director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Sarah Korman officer: General Counsel 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98660
Todd Bedrick officer: VP, CCPAO 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Joseph Sirosh director C/O COMPASS, INC., 155 AVENUE OF THE AMERICAS, SIXTH FLOOR, NEW YORK NY 10013
Sean Mcclain director, 10 percent owner, officer: President and Chief Executive 18105 SE MILL PLAIN BLVD, SUITE 350, VANCOUVER WA 98683
Zachariah Jonasson director 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Karen K Mcginnis director INSIGHT ENTERPRISES INC, 1305 WEST AUTO DRIVE, TEMPE AZ 85284
Redmile Biopharma Investments Ii, L.p. director, 10 percent owner LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129
Phoenix General Partner Ii Llc 10 percent owner 1700 S. EL CAMINO REAL, SUITE 335, SAN MATEO CA 94402
Nikhil Goel officer: Chief Business Officer 101 E. 6TH STREET, SUITE 350, VANCOUVER WA 98660